ClinicalTrials.govpublic full text
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
chronic myelogenous leukemia, cml, chronic myeloid leukemia, arsenic, arsenic trioxide, imatinib, dasatinib, nilotinib, tki, tyrosine kinase inhibitor, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 885083
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.